Daily Endocrinology Research Analysis
Analyzed 105 papers and selected 3 impactful papers.
Summary
Analyzed 105 papers and selected 3 impactful articles.
Selected Articles
1. Multi-omics reveals microbiota, metabolite, and immunological heterogeneity of age-related endotypes in type 1 diabetes.
Integrated multi-omics stratified pediatric T1D into distinct age-related endotypes with subgroup-specific microbiota, metabolite, and lipid signatures. A candidate Dialister invisus–docosapentaenoic acid–B-cell activation axis was identified and experimentally supported, offering mechanistic targets for precision intervention.
Impact: This work advances mechanistic understanding of T1D heterogeneity by linking microbiota-driven lipid mediators to B-cell activation, enabling precision endotyping. It integrates multiple omics with experimental validation, opening avenues for targeted modulation.
Clinical Implications: While not immediately practice-changing, the defined endotypes and the D. invisus–DPA axis suggest testable strategies (microbiota or lipid modulation) to tailor prevention or early immunomodulation by age-at-onset.
Key Findings
- Defined early-, intermediate-, and late-onset T1D endotypes with distinct microbiota (e.g., Acetatifactor, Firmicutes A, Bacteroidaceae) and metabolite/lipid signatures.
- Early-onset T1D showed the highest peripheral B-cell proportion and immune pathway upregulation; late-onset favored metabolic pathways.
- An integrated network and experiments implicated Dialister invisus promoting B-cell proliferation via docosapentaenoic acid (DPA), suggesting a mechanistic axis (DPA–STMN1).
Methodological Strengths
- Comprehensive multi-omics integration (microbiome, metabolome, lipidome, transcriptome) with age-stratified design
- Experimental validation supporting a candidate microbiota–lipid–immune axis
Limitations
- Cross-sectional design limits causal inference and temporal dynamics
- Pediatric cohort size is moderate and may not capture broader demographic or geographic diversity
Future Directions: Longitudinal validation of endotypes with intervention trials testing microbiota or lipid modulation (e.g., targeting DPA or Dialister invisus) and translation to biomarker panels for clinical stratification.
Type 1 diabetes (T1D) exhibits age-related heterogeneity in clinical progression and immune pathology, yet the underlying molecular mechanisms remain poorly understood. Here, we integrate microbiome, metabolome, lipidome, and transcriptome profiling from 108 newly diagnosed pediatric patients with T1D, along with 56 healthy controls, to investigate age-related endotypes. Patients were stratified into early-onset (E-T1D, <7 years), intermediate-onset (I-T1D, 7-12 years), and late-onset (L-T1D, ≥13 years) groups. Multi-omics analyses revealed distinct molecular signatures among T1D subgroups. The most enriched microbial signatures were the genus Acetatifactor in E-T1D, the phylum Firmicutes A in I-T1D, and the family Bacteroidaceae in L-T1D (Linear Discriminant Analysis scores = 3.49, 5.56, and 5.78, respectively). For metabolites, pipecolic acid increased most in E-T1D, testosterone in I-T1D, while N-acetylhomocitrulline was most enriched in L-T1D. Lipidomic profiling revealed subgroup-specific alterations, with increased levels of LPA(16:1) in E-T1D, TG(16:0/18:2/18:3) in I-T1D, and TG(18:0/18:1/18:1) in L-T1D. The proportion of peripheral B cells to total lymphocytes was the highest in E-T1D (median = 11.64%) and associated with upregulated immune-related pathways, lowest in L-T1D (median = 5.99%) and linked to metabolic processes, while I-T1D (median = 8.47%) exhibited intermediate features of both groups. Integration of multi-omics interaction networks and experimental validation revealed that the microbial species Dialister invisus may promote peripheral B cell proliferation via docosapentaenoic acid, potentially contributing to early-onset T1D. Together, these findings provide a molecular framework for understanding age-related T1D endotypes and suggest potential targets for precision intervention. Workflow and key findings of the study.A multi-omics integration strategy was applied to newly diagnosed pediatric type 1 diabetes (T1D) patients stratified by age at diagnosis: early-onset (E-T1D), intermediate-onset (I-T1D), and late-onset (L-T1D), to delineate age-related T1D endotypes. Comprehensive profiling included gut microbiome, serum metabolome, lipidome, and peripheral immune transcriptome analyses. An integrated multi-omics interaction network revealed 665 direct microbiota-gene connections and 2,608 microbiota-metabolite/lipid-gene triadic interactions, highlighting a D. invisus-docosapentaenoic acid (DPA)-STMN1 axis mediating B-cell activation in early-onset T1D.
2. Implementation of Intermittently Scanned Continuous Glucose Monitoring and Changes in Hospitalizations and Health Care Costs in Insulin-Treated Type 2 Diabetes.
Population-wide, publicly funded isCGM rollout in insulin-treated T2D reduced acute diabetes-related hospitalizations by 63%, shortened length of stay, and lowered inpatient costs, with modest HbA1c improvement.
Impact: Demonstrates real-world system-level impact of CGM beyond glycemic metrics, informing payers and policymakers about cost and hospitalization benefits.
Clinical Implications: Supports broader access to isCGM for insulin-treated T2D to prevent acute decompensations, with potential to embed CGM into standard care pathways and reduce hospital burden.
Key Findings
- Among 15,413 adults, acute diabetes-related hospitalization rates fell from 74.6 to 27.5 per 10,000 person-years (RR 0.37).
- Median length of stay decreased (4 to 3 days), and total inpatient costs decreased by ~$3.8 million.
- HbA1c improved by 0.44%, while cardiovascular hospitalization rates were stable, with ITS suggesting a favorable trend change post-implementation.
Methodological Strengths
- Large population-based quasi-experimental design with interrupted time series and Poisson modeling
- Hard clinical endpoints and cost analyses using administrative data
Limitations
- Non-randomized design susceptible to residual confounding and secular trends
- Outcome identification reliant on ICD-10 coding and administrative datasets
Future Directions: Evaluate differential benefits by subgroups (e.g., age, comorbidities, socioeconomic status), adherence patterns, and integration with decision-support to maximize health-system gains.
OBJECTIVE: To assess the effect of a population-wide implementation of intermittently scanned continuous glucose monitoring (isCGM) on hospitalization rates and trends, length of stay, and inpatient health care costs among adults with insulin-treated type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This population-based, longitudinal, quasi-experimental cohort study included adults with T2D taking multiple daily insulin injections who initiated publicly funded isCGM between April 2022 and December 2023. Hospitalizations for acute diabetes-related complications (diabetic ketoacidosis, hyperglycemic hyperosmolar state, simple hyperglycemia, and hypoglycemia) and cardiovascular complications (myocardial infarction, stroke, and major lower-extremity amputation) were identified using ICD-10 codes. Incidence rates and rate ratios (RRs) were estimated using Poisson models. Interrupted time series analyses were used to estimate counterfactual trends. RESULTS: Among 15,413 participants, the mean follow-up was 22.5 ± 4.6 months before and 19.1 ± 4.4 months after isCGM initiation. Mean HbA1c decreased from 8.09 to 7.65% (mean difference -0.44 [95% CI -0.47 to -0.42]). Diabetes-related hospitalization rates decreased from 74.6 to 27.5 per 10,000 person-years (RR 0.37 [95% CI 0.28-0.49]). Cardiovascular hospitalization rates remained stable (228.8 vs. 215.8 per 10,000 person-years; RR 0.94 [0.84-1.06]). Interrupted time series analyses showed a change in cardiovascular admission rates after isCGM initiation relative to the preintervention trend. Median length of stay decreased from 4 (interquartile range 5) to 3 (4) days. Total inpatient costs decreased by $3,806,776.90 (-$955,186.70 per 10,000 person-years). CONCLUSIONS: In this real-world study, implementation of isCGM among insulin-treated adults with T2D was associated with substantial reductions in acute diabetes-related hospitalizations, shorter hospital stays, lower health care costs, and changes in cardiovascular hospitalization trends.
3. Genetic screening of children for familial hypercholesterolaemia: the VRONI study.
A statewide two-step pediatric FH screening program combining LDL-C thresholds with panel/NGS testing found high variant prevalence (observed 1:90; bias-adjusted 1:163) and sharply rising diagnostic yield with higher LDL-C, demonstrating feasibility and informing national screening.
Impact: Provides robust, population-scale evidence that pediatric FH is more prevalent than assumed and that biochemical pre-screening efficiently triages genetic testing, directly informing policy.
Clinical Implications: Supports integrating LDL-C–triggered genetic testing into routine pediatric care, prioritizing sequencing over limited variant panels, and planning national programs for early detection and treatment.
Key Findings
- Among 25,431 children, 1,689 had LDL-C ≥3.36 mmol/L, with 17% of genetically tested children positive for FH-causing variants.
- Variant positivity rose from 4.7% at LDL-C 3.36–3.49 mmol/L to 78.6% above 5.17 mmol/L.
- Observed prevalence was 1:90; after correcting ascertainment bias, predicted prevalence was 1:163, aligning with gnomAD and UK Biobank benchmarks.
Methodological Strengths
- Large statewide screening with standardized biochemical trigger and combined panel/NGS testing
- Ascertainment bias quantified and corrected using generalized linear mixed models; external benchmark comparisons
Limitations
- Regional founder effect may inflate observed prevalence; generalizability beyond Bavaria may vary
- Cross-sectional screening without long-term clinical outcome tracking
Future Directions: Nationwide implementation studies with cost-effectiveness, cascade screening impacts, and longitudinal outcomes; evaluation of optimal LDL-C thresholds by age and sex.
BACKGROUND AND AIMS: The role of genetic testing as part of universal screening programmes for familial hypercholesterolaemia (FH) in children is not well defined. Here, a two-step approach to identify children carrying FH-causing variants was investigated. METHODS: In this study from Southern Germany, paediatricians were invited to offer FH screening to all children aged 4.8-14.9 years at routine paediatric examinations. The FH screening programme began in September 2020 in Bavaria and has involved up to 480 paediatricians. It included biochemical and genetic testing using 0.2 mL of blood taken from a fingertip. In case of low-density lipoprotein cholesterol (LDL-C) serum concentration ≥3.36 mmol/L (≥130 mg/dL), FH-causing variants were determined in the same sample with a focused panel covering most frequent variants (n = 48) and sequencing of relevant genes. RESULTS: Out of 25 431 children screened so far, 1689 children had an LDL-C ≥ 3.36 mmol/L (>130 mg/dL), which defined this concentration as the 93rd percentile. Pathogenic variants were identified by the focused panel in 157 and by next-generation sequencing in 283 children, respectively. While 17% (283/1670) of all genetically analysed children tested positive, the fraction of individuals with FH-causing variants increased across the spectrum of LDL-C serum concentrations from 4.7% (23/492) at 3.36-3.49 mmol/L (130-135 mg/dL) to 78.6% (81/103) above 5.17 mmol/L (200 mg/dL). Overall, the prevalence of FH-causing variants was high (1:90). One reason was a founder variant (n = 63) within the LDLR gene, found 40 times more frequent than European average. The analysis of recruitment data revealed significant ascertainment bias, with lower recruitment rate practices exhibiting higher prevalence. After adjustment for the bias using a generalized linear mixed model, the predicted prevalence was 1 in 163 (0.61%), which is highly consistent with large-scale genomic benchmarks as gnomAD (1:165, n = 622 057) and the UK Biobank (1:176, n = 48 741). CONCLUSIONS: The prevalence of FH determined in this study is significantly higher than previously published estimates (∼1:250), highlighting the importance of this condition for public health and supporting calls for a national paediatric screening programme, given the availability of effective treatment options. For children between 5 and 15 years, biochemical screening is an effective way to select patients for genetic testing, with sequencing of candidate genes being superior to variant screening. In summary, the VRONI study demonstrates the feasibility and efficacy of a combined biochemical and genetic screening for FH in children.